Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$87 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-7.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1236.3
Industry P/E
--
EV/EBITDA
-1.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.4
Face value
--
Shares outstanding
107,606,376
CFO
CA$-190.21 Mln
EBITDA
CA$-202.28 Mln
Net Profit
CA$-224.13 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Oncolytics Biotech - ADR
| 9.9 | -15.0 | 9.9 | 82.3 | -7.1 | -24.1 | -11.6 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Oncolytics Biotech - ADR
| -4.4 | -17.2 | 17.3 | -41.6 | -50.0 | 163.0 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Oncolytics Biotech - ADR
|
1.0 | 86.6 | 0.0 | -35.3 | -- | -1067.3 | -- | 1,236.3 |
| 69.9 | 669.9 | 0.0 | -19.8 | -- | -28.1 | -- | 10.8 |
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the... treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada. Address: 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5 Read more
President, CEO & Director
Dr. Matthew C. Coffey M.B.A., Ph.D.
President, CEO & Director
Dr. Matthew C. Coffey M.B.A., Ph.D.
Headquarters
Calgary, AB
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Oncolytics Biotech Inc - ADR is $0.96 (NASDAQ) as of 02-Apr-2026 12:32 EDT. Oncolytics Biotech Inc - ADR has given a return of -7.15% in the last 3 years.
Since, TTM earnings of Oncolytics Biotech Inc - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-2.19
|
11.62
|
|
2023
|
-4.84
|
3.61
|
|
2022
|
-5.09
|
3.66
|
|
2021
|
-3.64
|
2.12
|
|
2020
|
-5.92
|
4.01
|
The 52-week high and low of Oncolytics Biotech Inc - ADR are Rs 1.51 and Rs 0.33 as of 02-Apr-2026.
Oncolytics Biotech Inc - ADR has a market capitalisation of $ 87 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Oncolytics Biotech Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.